RITA is primarily used in cancer research due to its ability to reactivate the p53 tumor suppressor pathway. It works by preventing the degradation of p53, allowing it to accumulate and trigger apoptosis in cancer cells. This makes RITA a valuable tool in studying targeted therapies for tumors with wild-type p53. It has shown activity in preclinical models against various cancer types, including leukemia, melanoma, and solid tumors. Researchers also use Rita to investigate mechanisms of apoptosis and cellular stress responses. Its selective action on p53-expressing cells offers a potential strategy for minimizing damage to healthy tissues in anticancer drug development.